Smart drug delivery technologies for Inflammatory Bowel Diseases (IBD) focus on site-specific therapeutic delivery, enhancing treatment efficacy while minimizing side effects. Recent advancements, including ingestible smart capsules, offer precise targeting within the gastrointestinal (GI) tract. Despite previous commercialization challenges, progress in technology, miniaturization, and component design has reignited interest. Smart capsules, equipped with drug reservoirs, sensors, and localization mechanisms, promise improved treatment for IBD by accurately releasing drugs at disease sites, overcoming limitations of traditional drug delivery methods.
Trending
- Signatera™ Receives Regulatory Approval in Japan for Colorectal Cancer (Business Wire)
- Century Health and Arizona Gastrointestinal Associates Partner to Accelerate Real-World Evidence in IBD and MASH (PR Newswire)
- EF-YOLO: A novel AI model for high-precision detection of colorectal polyps (EurekAlert)
- Who’s winning, losing the physician practice acquisition race? (Becker’s Healthcare)
- Clinician-Industry Collaboration: A Clinical Review of Ethical, Strategic, and Practical Considerations (GI & Endoscopy News)
- Wanna Be Startin’ Somethin’? Advice for Initiating a New Line of Service (GI & Endoscopy News)
- The robotic penguin that makes endoscopy optional (Technology.org)
- Peptides, Colonoscopy, and the Inversion of Risk (Medscape)
